AcelRx Pharmaceuticals Inc

Type: Company
Name: AcelRx Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.acelrx.com/
First reported Jun 18 2013 - Updated 15 hours ago - 2 reports

Jefferies Group Reiterates “Buy” Rating for AcelRx Pharmaceuticals (ACRX)

AcelRx Pharmaceuticals (NASDAQ: ACRX) ‘s stock had its “buy” rating restated by analysts at Jefferies Group in a research report issued to clients and investors on Tuesday, StockRatingsNetwork.com reports. They currently have a $13.00 price objective ... [Published Mideast Time - 15 hours ago]
First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

BIO-TECH STOCKS: AcelRx Pharmaceuticals Inc, Bristol Myers Squibb Co., ImmunoCellular Therapeutics Ltd, Infinity Pharmaceuticals Inc.

Huntington Beach, CA -- (SBWIRE) -- 06/18/2013 -- PSPicks.com provides its subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks traded on the NASDAQ, ... [Published SBWire - Jun 18 2013]
First reported Jun 10 2013 - Updated Jun 10 2013 - 1 reports

Market Report, "AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2013", published

(live-PR.com) - Global Market Direct's pharmaceuticals report, "AcelRx Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the AcelRx Pharmaceuticals, Inc.'s research and development focus. The report includes information on current ... [Published Live-PR.com - Jun 10 2013]
First reported Jun 03 2013 - Updated Jun 04 2013 - 1 reports
Affymax Inc
Affymax Inc

Affymax, Inc. (NASDAQ:AFFY) and AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Added to Growing Stock Report's NASDAQ Decliners Watch List.

New York, NY -- (SBWIRE) -- 06/03/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Affymax, Inc. (NASDAQ:AFFY) and AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX).Affymax, Inc. (NASDAQ:AFFY) a biopharmaceutical company that ... [Published SBWire - Jun 03 2013]
First reported May 29 2013 - Updated May 30 2013 - 2 reports

ADRIAN ADAMS of AcelRx Pharmaceuticals, Inc. (ACRX)-Nasdaq bought Shares of ACRX

Reported by InsiderCow.com at 2013-05-29 12:20:20 ET ADRIAN ADAMS, director of AcelRx Pharmaceuticals, Inc. (ACRX)-Nasdaq bought 50,000 shares of ACRX from the open market on 2013-05-29. The stock was up 5.60% after the InsiderCow.com report.Trade amount: ... [Published Individual.com - May 30 2013]
First reported May 29 2013 - Updated May 29 2013 - 1 reports
AcelRx Pharmaceuticals Inc
AcelRx Pharmaceuticals Inc

Form 4 ACELRX PHARMACEUTICALS For: May 24 Filed by: ADAMS ADRIAN

StreetInsider.com - Form 4 ACELRX PHARMACEUTICALS For: May 24 Filed by: ADAMS ADRIAN ... [Published Street Insider - May 29 2013]
First reported May 29 2013 - Updated May 29 2013 - 1 reports

AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare

ACELRX PHARMACEUTICALS INC Symbol U : ACRX Recent Sedar Documents AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare ... [Published Stockwatch - May 29 2013]
First reported May 29 2013 - Updated May 29 2013 - 1 reports

AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare

/PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, ... [Published FinanzNachrichten.de - May 29 2013]
First reported May 22 2013 - Updated May 22 2013 - 1 reports

Canaccord Boosts PT on AcelRx (ACRX) to $11; On Track for Sufentanil NDA Submission by Q313

AcelRx (Nasdaq: ACRX) is positive Wednesday after announcing late Tuesday that the primary endpoint was met in a placebo-controlled Phase 3 study of its investigational sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System (NanoTab ... [Published Street Insider - May 22 2013]
First reported May 22 2013 - Updated May 22 2013 - 2 reports

AcelRx Pharmaceuticals Given New $11.00 Price Target at Canaccord Genuity (ACRX)

Equities research analysts at Canaccord Genuity lifted their price target on shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) to $11.00 in a research note issued to investors on Wednesday, StockRatingsNetwork reports.A number of other firms have also recently ... [Published The Utah People's Post - May 22 2013]
First reported May 21 2013 - Updated May 21 2013 - 4 reports

4 Healthcare Stock Stories For Tuesday Investment Wellness

Boston Scientific Corporation ( NYSE:BSX ): Closing price $9.23 Five-year data from the Asthma Intervention Research 2 clinical trial presented on Tuesday showed that the Boston Scientific Corporation Alair Bronchial Thermoplasty System continues ... [Published Wall St. Cheat Sheet - May 21 2013]
First reported May 21 2013 - Updated May 21 2013 - 2 reports

AcelRx pain treatment meets late-stage study goals

REDWOOD CITY, Calif. -- Shares of AcelRx Pharmaceuticals Inc. hit an all-time high price Tuesday, after the specialty drugmaker said its NanoTab pain treatment system met its main goal in late-stage research, and the company is preparing to submit it ... [Published CNBC - May 21 2013]

Quotes

..." CMO West speaker Santosh Vetticaden, PhD, MD, CMO, SVP, Mast Therapeutics, Inc., said, "I found the East Coast meeting extremely useful since it was designed exclusively to addressing CMO interests. The opportunity to network with my peers at this event was invaluable since, barring this meeting, interactions I have with my peers tend to be at scientific meetings where the focus is the scientific meeting and not the CMO peer interactions." About : has a very specific focus – developing specialized events both public and private as well as research groups and advisory boards for professionals...
Chief Medical Officer Summit for Biotechs Goes West [Published PRWeb - Jun 17 2013]
...in all three Phase III studies in which the Sufentanil NanoTab PCA System has been evaluated," said Richard King, president and CEO of AcelRx. "We remain on track for a third quarter 2013 NDA submission for the NanoTab System, a product which, if approved, will present AcelRx with an opportunity to fundamentally redefine the management of post-operative pain for tens of millions of patients both in the US and around the world."
AcelRx's Phase III post-operative pain study meets primary efficacy endpoint [Published Individual.com - Jun 10 2013]
...As Marta Martinez, the Head of Sales at AOL said, "By certifying all our sales employees and ensuring that they have a deep understanding of the interactive advertising platforms, technologies, and capabilities that impact the industry, we are demonstrating our dedication to our clients and staying ahead of the curve." In technical analysis, shares of AOL's stock crossed below their 200-day moving average of $35.08 yesterday...
In Insider Trading, AOL Sees a Purchase and Phillip Frost Buys Shares of Ladenburg Thalmann [Published Minyanville - May 30 2013]
...505(b)(2) is a New Drug Application NDA) that contains full safety and efficacy reports from clinical trials, but allows, "at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference" according to the FDA's PCCA Relationship/Drug Discovery Platform
Imprimis' Platform Set To Bring Library Drug Formulations Quickly To Market [Published Seeking Alpha - May 30 2013]

More Content

All (80) | News (47) | Reports (8) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (13)
sort by: Date | Relevance
Jefferies Group Reiterates “Buy” Rating for Ace... [Published Mideast Time - 15 hours ago]
BIO-TECH STOCKS: AcelRx Pharmaceuticals Inc, Br... [Published SBWire - Jun 18 2013]
UPDATE: Jefferies Raises PT on AcelRx Pharmaceu... [Published Benzinga.com - Jun 18 2013]
AcelRx Pharmaceuticals Given a $13.00 Price Tar... [Published American Banking News - Jun 18 2013]
Investment Analysts’ Price Target Changes for J... [Published American Banking News - Jun 18 2013]
Chief Medical Officer Summit for Biotechs Goes ... [Published PRWeb - Jun 17 2013]
Top Insider Trades 6/10/13: ARSD, USCR, AMTD, MRC [Published Seeking Alpha - Jun 11 2013]
Form 4 ACELRX PHARMACEUTICALS For: Jun 06 Filed... [Published Street Insider - Jun 10 2013]
Market Report, "AcelRx Pharmaceuticals, Inc. - ... [Published Live-PR.com - Jun 10 2013]
AcelRx's Phase III post-operative pain study me... [Published Individual.com - Jun 10 2013]
PRE-MARKET MOST ACTIVES: AcelRx Pharmaceuticals... [Published SBWire - Jun 06 2013]
Affymax, Inc. (NASDAQ:AFFY) and AcelRx Pharmace... [Published SBWire - Jun 03 2013]
5 of Last Week's Biggest Winners [Published Motley Fool - Jun 02 2013]
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) and ... [Published SBWire - May 31 2013]
4 Top Small Cap Biotech Acquisition Targets [Published Seeking Alpha - May 31 2013]
In Insider Trading, AOL Sees a Purchase and Phi... [Published Minyanville - May 30 2013]
ADRIAN ADAMS of AcelRx Pharmaceuticals, Inc. (A... [Published Individual.com - May 30 2013]
Top Insider Trades: LTS MCK AOL CMO [Published TheStreet.com - May 30 2013]
Top Insider Trades 5/29/13: LTS, MCK, AOL, CMO [Published Seeking Alpha - May 30 2013]
Imprimis' Platform Set To Bring Library Drug Fo... [Published Seeking Alpha - May 30 2013]
Wednesday 5/29 Insider Buying Report: ACRX, CSV [Published Individual.com - May 29 2013]
Form 4 ACELRX PHARMACEUTICALS For: May 24 Filed... [Published Street Insider - May 29 2013]
Infinata's BioPharm Insight Releases its Cataly... [Published Individual.com - May 29 2013]
AcelRx Pharmaceuticals to Present at the Jeffer... [Published Stockwatch - May 29 2013]
AcelRx Pharmaceuticals to Present at the Jeffer... [Published FinanzNachrichten.de - May 29 2013]
AcelRx Pharmaceuticals to Present at the Jeffer... [Published PR Newswire: Health - May 29 2013]
This Week in Biotech [Published EquityJungle - v0.1 - May 25 2013]
Big Downside Reversal [Published Zecco - May 22 2013]
Stock Analysts’ Price Target Changes for May, 2... [Published American Banking News - May 22 2013]
NanoTab Pain Treatment Meets Goals [Published Drug Discovery and Development - May 22 2013]
1 2 3
In Focus
  •  
Adrian Adams, Jim Welch, Richard King, [more]
  •  
Canaccord Genuity Corp, Jefferies Group Inc, UBS AG, [more]
  •  
Federal Aviation Administration, FDA Food & Drug Administration, SEC US Securities & Exchange Commission, [more]
  •  
8-k, breakthrough pain, Sufentanil, [more]
  •  
Boeing 787, Bavituximab, Xarelto, [more]
  •  
Bangalore, Denver (Colorado, United States), Philadelphia (Pennsylvania, United States), [more]
  •  
Cameroon, United States, China, [more]
  •  
Diseases, Medication, Research & Development, [more]
  •  
IT, Telecom, Accounting, [more]
SEC Filings, PR Newswire: General Business, PR Newswire: Health, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
This Week in Biotech [Published EquityJungle - v0.1 - May 25 2013]
Filed under: Investing With the  SPDR S&P Biotech Index  up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, ...
4 Healthcare Stock Stories For Tuesday Investme... [Published Wall St. Cheat Sheet - May 21 2013]
Boston Scientific Corporation ( NYSE:BSX ): Closing price $9.23 Five-year data from the Asthma Intervention Research 2 clinical trial presented on Tuesday showed that the Boston Scientific Corporation Alair Bronchial Thermoplasty System continues ...
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: US... [Published Proactiveinvestors United Kingdom website - May 02 2013]
US equities look to open in minor positive territory, erasing some of the large losses seen during yesterday's session. Focus today has been on the ECB rate decision where the central bank cut their main refi rate by 25bps and the marginal lending rate ...
3 Healthcare Stock Stories for Midweek Investme... [Published Wall St. Cheat Sheet - Apr 25 2013]
Cerus Corporation ( NASDAQ:CERS ): Closing price $5.22 On Wednesday, Cerus announced that the FDA has accepted its proposed modular Premarket Approval application shell for review of the INTERCEPT Blood System for platelets. A PMA shell is a description ...
GM Sparks Electric Vehicle Program, Sprint Beat... [Published Wall St. Cheat Sheet - Apr 24 2013]
General Motors ( NYSE:GM ): The new generation Spark, one of GM’s compact offerings, may get nearly double the range  of the Volt once the same plug-in drive train is shoe-horned into the vehicle this summer. EPA estimates put the combined mileage ...
1 2 3

Press Releases

sort by: Date | Relevance
AcelRx Pharmaceuticals to Present at the Jeffer... [Published PR Newswire: Health - May 29 2013]
Top-line Data Demonstrate Primary Endpoint Achi... [Published PR Newswire: General Business - May 21 2013]
AcelRx Pharmaceuticals to Present at the UBS Gl... [Published PR Newswire: General Business - May 16 2013]
AcelRx Pharmaceuticals Reports First Quarter 20... [Published PR Newswire: Financial Services - May 08 2013]
AcelRx Pharmaceuticals to Hold First Quarter 20... [Published PR Newswire: Health - May 03 2013]
1 2 3
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.